According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

Dupixent has emerged as a significant growth driver for Regeneron, showing impressive uptake in atopic dermatitis and asthma. The drug's potential expansion into new indications, such as chronic ...

Regeneron stock has trended bearishly since ... These indications include asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, among others.

Regeneron recently announced that the primary ... Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and ...

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

driven by continued strong prescription trends in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis and prurigo nodularis. Hence, Regeneron has ...

Regeneron does not undertake any obligation ... Three of these indications, atopic dermatitis, asthma, and nasal polyps have achieved blockbuster status, each generating over $1 billion in annual ...